AGIO - חוב כולל להון Agios Corp

This daily price chart of the total debt-to-equity ratio for Agios Pharmaceuticals (AGIO) on GURU.Markets reflects a value of 0.03. Agios Pharmaceuticals (AGIO) maintains a flawless reputation as an innovator in the treatment of orphan diseases. The business relies on developing unique therapies for patients with genetic metabolic disorders, which ensures a steady stream of income. However, the risk of new product delays is linked to global instability and supply chain disruptions.

This ratio determines the degree of business dependence on borrowed funds by comparing total liabilities to equity to assess financial stability and default risks. By analyzing the total debt-to-equity ratio, investors determine the margin of safety for Agios Pharmaceuticals (AGIO), whose drug development model for rare pathologies relies on standard laboratory capacities without active environmental investments.